Cryoport Returns to Profitability, Eyes 5 New CGT Approvals in 2026

Key Facts

1Cryoport returned to adjusted EBITDA profitability in 2Q26, with positive operating cash flow of $8 million TTM.

2Management expects 5 new cell and gene therapy commercial approvals in 2026.

3The Phase 3 trial pipeline increased 15% YoY to 94 trials, supporting future growth.

Cryoport returned to adjusted EBITDA profitability in the second quarter of 2026, recording positive operating cash flow of $8 million on a trailing twelve-month basis. Seeking Alpha reported that management expects 5 new cell and gene therapy commercial approvals during 2026, strengthening its position in life science services.

The company's Phase 3 trial pipeline increased 15% year-over-year to reach 94 trials, supporting future growth prospects. Regarding market performance, CYRX closed at $17.40 on September 24, 2026, after trading between a session low of $17.25 and a high of $17.98.